A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47–57) improve cytotoxic immune responses

[1]  Tahoora Mousavi,et al.  Molecular prevalence and phylogenetic analysis of human papillomavirus in normal cervical samples from northern Iran , 2020 .

[2]  Juan Du,et al.  Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study , 2020, European Respiratory Journal.

[3]  Tahoora Mousavi,et al.  Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review , 2019, Archives of Virology.

[4]  O. Picconi,et al.  Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease , 2019, Vaccines.

[5]  Zhiwei Wu,et al.  Induction of neutralizing antibodies by human papillomavirus vaccine generated in mammalian cells , 2019, Antibody therapeutics.

[6]  S. Ferrero,et al.  New prophylactics human papilloma virus (HPV) vaccines against cervical cancer , 2018, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[7]  Tahoora Mousavi,et al.  The prevalence and genotyping of human papillomavirus in patients with oral tumors in health centers and clinics of Mazandaran in Iran , 2018, VirusDisease.

[8]  A. Bolhassani,et al.  Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines , 2018, International immunopharmacology.

[9]  E. Androphy,et al.  Regulation of the Papillomavirus E6 and E7 Oncoproteins By the Viral E1 and E2 Proteins , 2018 .

[10]  Y. Haupt,et al.  Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells* , 2018, Molecular & Cellular Proteomics.

[11]  X. Pu,et al.  A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect. , 2017, Vaccine.

[12]  M. Moosazadeh,et al.  Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis , 2017, International journal of preventive medicine.

[13]  A. Abdoli,et al.  The effects of CpG‐ODNs and Chitosan adjuvants on the elicitation of immune responses induced by the HIV‐1‐Tat‐based candidate vaccines in mice , 2017, Pathogens and disease.

[14]  Boting Zhou,et al.  Progress in Research and Application of HIV-1 TAT-Derived Cell-Penetrating Peptide , 2017, The Journal of Membrane Biology.

[15]  Qiang Huang,et al.  Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58 , 2016, Scientific Reports.

[16]  W. Xu,et al.  Adjuvant effect of docetaxel on HPV16 L2E6E7 fusion protein vaccine in a mouse model. , 2016, International immunopharmacology.

[17]  M. Moosazadeh,et al.  Human papillomavirus and breast cancer in Iran: a meta- analysis , 2016, Iranian journal of basic medical sciences.

[18]  M. Gómez-Lim,et al.  Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model , 2014, Archives of Virology.

[19]  M. Gómez-Lim,et al.  Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model , 2013, Archives of Virology.

[20]  O. Levy,et al.  Immune response to vaccine adjuvants during the first year of life. , 2013, Vaccine.

[21]  Peter Cresswell,et al.  Pathways of antigen processing. , 2013, Annual review of immunology.

[22]  Changfei Li,et al.  TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses. , 2013, Vaccine.

[23]  B. Ni,et al.  A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice. , 2012, Vaccine.

[24]  John T. Bates,et al.  Direct Stimulation of tlr5+/+ CD11c+ Cells Is Necessary for the Adjuvant Activity of Flagellin1 , 2009, The Journal of Immunology.

[25]  S. Miller,et al.  Helper T cell subsets and control of the inflammatory response , 2008 .

[26]  Chang-Hyun Kim,et al.  Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12 , 2006, Cancer Immunology, Immunotherapy.

[27]  W. Ahn,et al.  CpG‐ODN‐stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen‐specific antitumour immunity in a HPV 16 E7‐associated animal tumour model , 2004, Immunology.

[28]  T. Eberlein,et al.  Induction of Antigen-Specific CTL by Recombinant HIV Trans-Activating Fusion Protein-Pulsed Human Monocyte-Derived Dendritic Cells 1 , 2003, The Journal of Immunology.

[29]  S. Moretti,et al.  Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses1 , 2002, The Journal of Immunology.

[30]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[31]  P. Romero,et al.  OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway , 2000, Nature Immunology.

[32]  I. Hakim,et al.  Enhanced major histocompatibility complex class I-dependent presentation of antigens modified with cationic and fusogenic peptides , 2000, Nature Biotechnology.

[33]  H. Rammensee,et al.  Cross-Presentation of Glycoprotein 96–Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis , 2000, The Journal of experimental medicine.

[34]  C. Harding,et al.  Pathways of antigen processing. , 1991, Current opinion in immunology.

[35]  Meiqin Zheng,et al.  Iranian Journal of Basic Medical Sciences , 2022 .